Our Philadelphia MRI contrast dye injury lawyers represent people who have suffered serious injury after undergoing an MRI with gadolinium contrast. Gadolinium, a contrast dye that improves and clarifies images taken with an MRI or MRA, can cause serious side effects, including gadolinium deposition disease (GDD).
Contrast Dye MRIs and Gadolinium Deposition Disease
MRI (magnetic resonance imaging) scans take images of patients’ internal organs and tissues with magnetic field and radio waves rather than x-rays. MRIs can be given with or without “contrast.” Patients receiving contrast MRIs are given an injected dye (usually gadolinium-based) that allows for clearer and more detailed MRI images. The dye enables radiologists and treating physicians to more accurately identify and diagnose internal abnormalities.
Gadolinium-based contrast dyes, also known as gadolinium-based contrast agents (GBCAs), can accumulate in the body and lead to gadolinium deposition disease. Gadolinium deposition disease is a painful, debilitating, and permanent condition that occurs when a patient with normal to near-normal kidney function is unable to rid his or her body of gadolinium from an MRI or MRA with contrast.
Symptoms of gadolinium deposition disease can occur within hours to a few months after the patient undergoes a gadolinium-based contrast MRI. Patients suffering from gadolinium deposition disease may experience:
- joint and bone pain
- brain fog and cognitive impairment
- chronic headaches
- ligament and tendon pain
- arm, leg, and torso pain (burning, pins and needles, and / or cutting sensations)
- thickening of subcutaneous soft tissue, tendons, and ligaments
- tightening / stiffness of hands and feet
- kidney damage
Gadolinium Contrast Dye MRI Warnings
On December 19, 2017, the U.S. Food and Drug Administration (FDA) required a new warning and additional safety measures for all gadolinium-based MRI contrast agents (GBCAs). The new warning stated that gadolinium dyes used in contrast MRIs can remain in the brain and other parts of the body for months or years after receiving the MRI drug.
On May 16, 2018, the FDA approved new patient medication guides for all gadolinium-based contrast agents (GBCAs).
- gadolinium contrast dyes can remain in patients’ bodies for months to years after receiving a dye injection
- patients’ bones retain the highest levels of gadolinium and retain it for a longer time than do other body parts
- the next highest concentrations of gadolinium are retained in patients’ brains, kidneys, liver, spleen, and other organs
- gadolinium retention can occur even in patients who have normal kidney function at the time an MRI is administered
The joint warning was issued for the following gadolinium-based contrast agents (GBCA):
- Dotarem (manufacturer Guerbet LLC)
- Eovist (manufacturer Bayer HealthCare Pharmaceuticals, Inc.)
- Gadavist (manufacturer Bayer HealthCare Pharmaceuticals, Inc.)
- Magnevist (manufacturer Bayer HealthCare Pharmaceuticals, Inc.)
- MultiHance (manufacturer Bracco Diagnostics, Inc.)
- Omniscan (manufacturer GE Healthcare)
- OptiMARK (manufacturer Guerbet / Liebel-Flarsheim Company LLC)
- ProHance (manufacturer Bracco Diagnostics, Inc.)
MRI Contrast Dye Gadolinium Lawsuits
Lawsuits commenced by Philadelphia MRI contrast dye injury lawyers may allege that manufacturers of gadolinium-based contrast MRI dyes:
- produced and marketed an unreasonably dangerous product
- knew or should have known of the significant risks associated with use of gadolinium-based contrast agents (GBCAs)
- failed to provide adequate warnings of the dangers associated with gadolinium retention, including gadolinium deposition disease
Contact our Philadelphia MRI Contrast Dye Injury Lawyers
If you or a loved one has developed serious injury, including gadolinium deposition disease, after an MRI or MRA with contrast, you may be entitled to compensation through legal action. Contact our Philadelphia MRI contrast dye injury lawyers, today, for a free consultation about your case.